Insider Transactions in Q3 2024 at Pacira Bio Sciences, Inc. (PCRX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
500
-0.43%
|
$6,000
$12.86 P/Share
|
|
Aug 16
2024
|
Laura Brege Director |
BUY
Open market or private purchase
|
Direct |
1,000
+5.39%
|
$12,000
$12.81 P/Share
|
|
Aug 16
2024
|
Marcelo Bigal Director |
BUY
Open market or private purchase
|
Direct |
1,512
+12.97%
|
$19,656
$13.25 P/Share
|
|
Aug 14
2024
|
Michael J. Yang Director |
BUY
Open market or private purchase
|
Direct |
2,000
+21.67%
|
$24,000
$12.9 P/Share
|
|
Aug 12
2024
|
Frank D. Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,264
+7.12%
|
$99,168
$12.1 P/Share
|
|
Aug 12
2024
|
Marcelo Bigal Director |
BUY
Open market or private purchase
|
Direct |
3,400
+28.26%
|
$40,800
$12.01 P/Share
|
|
Aug 12
2024
|
Mark Froimson Director |
BUY
Open market or private purchase
|
Direct |
1,400
+8.82%
|
$15,400
$11.58 P/Share
|
|
Aug 02
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
945
-0.99%
|
$18,900
$20.05 P/Share
|
|
Aug 01
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
305
-0.32%
|
$6,100
$20.75 P/Share
|
|
Jul 02
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,836
-2.88%
|
$79,408
$28.25 P/Share
|
|
Jul 01
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
914
-0.92%
|
$25,592
$28.46 P/Share
|